Efficacy monitoring using amyloid and tau PET imaging in Down syndrome populations

This study examines the use of positron emission tomography (PET) imaging to monitor amyloid and tau biomarkers as measures of treatment efficacy in individuals with Down syndrome. The research applies established neuroimaging methodology to track Alzheimer's-related pathology in this population, which has elevated risk for early-onset cognitive decline.